Seminars in Radiation Oncology
Volume 17, Issue 3 , Pages 230-242 , July 2007

Pediatric Hodgkin Lymphoma: Maximizing Efficacy and Minimizing Toxicity

  • David C. Hodgson, MD, MPH

      Affiliations

    • Radiation Medicine Program, Princess Margaret Hospital, University Health Network, and Department of Radiation Oncology, University of Toronto, Toronto, Canada.
    • Corresponding Author InformationAddress reprint requests to David C. Hodgson, MD, MPH, Department of Radiation Oncology, 610 University Avenue, Toronto M5G 2M9, Canada.
    • ,
  • Melissa M. Hudson, MD

      Affiliations

    • Department of Clinical Oncology, St. Jude Children’s Research Hospital, University of Tennessee College of Medicine, Memphis, TN.
    • ,
  • Louis S. Constine, MD

      Affiliations

    • Departments of Radiation Oncology and Pediatrics, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY.

References 

  1. Donaldson SS, Kaplan HS. Complications of treatment of Hodgkin’s disease in children. Cancer Treat Rep. 1982;66:977–989
  2. Mauch PM, Weinstein H, Botnick L, et al. An evaluation of long-term survival and treatment complications in children with Hodgkin’s disease. Cancer. 1983;51:925–932
  3. Armstrong AA, Alexander FE, Cartwright R, et al. Epstein-Barr virus and Hodgkin’s disease: Further evidence for the three disease hypothesis. Leukemia. 1998;12:1272–1276
  4. Andersson J. Epstein-Barr virus and Hodgkin’s lymphoma. Herpes. 2006;13:12–16
  5. Jarrett RF. Viruses and Hodgkin’s lymphoma. Ann Oncol. 2002;13(suppl 1):23–29
  6. Spitz MR, Sider JG, Johnson CC, et al. Ethnic patterns of Hodgkin’s disease incidence among children and adolescents in the United States, 1973-82. J Natl Cancer Inst. 1986;76:235–239
  7. Westergaard T, Melbye M, Pedersen JB, et al. Birth order, sibship size and risk of Hodgkin’s disease in children and young adults: A population-based study of 31 million person-years. Int J Cancer. 1997;72:977–981
  8. Chang ET, Zheng T, Weir EG, et al. Childhood social environment and Hodgkin’s lymphoma: New findings from a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2004;13:1361–1370
  9. Alexander FE, Jarrett RF, Lawrence D, et al. Risk factors for Hodgkin’s disease by Epstein-Barr virus (EBV) status: Prior infection by EBV and other agents. Br J Cancer. 2000;82:1117–1121
  10. Jarrett RF, Krajewski AS, Angus B, et al. The Scotland and Newcastle epidemiological study of Hodgkin’s disease: Impact of histopathological review and EBV status on incidence estimates. J Clin Pathol. 2003;56:811–816
  11. Alexander FE, Lawrence DJ, Freeland J, et al. An epidemiologic study of index and family infectious mononucleosis and adult Hodgkin’s disease (HD): evidence for a specific association with EBV+ve HD in young adults. Int J Cancer. 2003;107:298–302
  12. Jaffe ES, Harris NL, Stein H, et al. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. In:  Kleihues P,  Sobin LH editor. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2001;
  13. Cleary SF, Link MP, Donaldson SS. Hodgkin’s disease in the very young. Int J Radiat Oncol Biol Phys. 1994;28:77–83
  14. Parkes SE, Coad NA, Muir KR, et al. Hodgkin’s disease in children in the West Midlands, 1957-1986: A large population-based study. Pediatr Hematol Oncol. 1994;11:471–486
  15. Kaplan HS. Hodgkin’s Disease. (ed 2). Cambridge, Massachusetts: Harvard University Press; 1980;
  16. White L, McCourt BA, Isaacs H, et al. Patterns of Hodgkin’s disease at diagnosis in young children. Am J Pediatr Hematol Oncol. 1983;5:251–257
  17. Blair A, Linos A, Stewart PA, et al. Evaluation of risks for non-Hodgkin’s lymphoma by occupation and industry exposures from a case-control study. Am J Ind Med. 1993;23:301–312
  18. Vinnicombe SJ, Reznek RH. Computerised tomography in the staging of Hodgkin’s disease and non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2003;30(suppl 1):S42–S55
  19. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. (ed 6). New York: Springer-Verlag; 2002;
  20. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630–1636
  21. Ng AK, Bernardo MV, Silver B, et al. Mid- and post-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 2005;61:175–184
  22. Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma. Am J Med. 2002;112:262–268
  23. Van Den Bossche B, Lambert B, De Winter F, et al. 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients. Nucl Med Commun. 2002;23:1079–1083
  24. Hasenclever D. The disappearance of prognostic factors in Hodgkin’s disease. Ann Oncol. 2002;13(suppl 1):75–78
  25. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease (International Prognostic Factors Project on Advanced Hodgkin’s Disease). N Engl J Med. 1998;339:1506–1514
  26. Smith RS, Chen Q, Hudson MM, et al. Prognostic factors for children with Hodgkin’s disease treated with combined-modality therapy. J Clin Oncol. 2003;21:2026–2033
  27. Bader SB, Weinstein H, Mauch P, et al. Pediatric stage IV Hodgkin disease (Long-term survival). Cancer. 1993;72:249–255
  28. Maity A, Goldwein JW, Lange B, et al. Mediastinal masses in children with Hodgkin’s disease (An analysis of the Children’s Hospital of Philadelphia and the Hospital of the University of Pennsylvania experience). Cancer. 1992;69:2755–2760
  29. Specht L. Prognostic factors in Hodgkin’s disease. Semin Radiat Oncol. 1996;6:146–161
  30. Bonadonna G, Valagussa P, Santoro A. Prognosis of bulky Hodgkin’s disease treated with chemotherapy alone or combined with radiotherapy. Cancer Surv. 1985;4:439–458
  31. Gobbi PG, Cavalli C, Gendarini A, et al. Reevaluation of prognostic significance of symptoms in Hodgkin’s disease. Cancer. 1985;56:2874–2880
  32. Bayle-Weisgerber C, Lemercier N, Teillet F, et al. Hodgkin’s disease in children (Results of therapy in a mixed group of 178 clinical and pathologically staged patients over 13 years). Cancer. 1984;54:215–222
  33. Gehan EA, Sullivan MP, Fuller LM, et al. The intergroup Hodgkin’s disease in children (A study of stages I and II). Cancer. 1990;65:1429–1437
  34. Donaldson SS, Glatstein E, Rosenberg SA, et al. Pediatric Hodgkin’s disease (II. Results of therapy). Cancer. 1976;37:2436–2447
  35. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’s disease: Report from the Late Effects Study Group. J Clin Oncol. 2003;21:4386–4394
  36. Green DM, Gingell RL, Pearce J, et al. The effect of mediastinal irradiation on cardiac function of patients treated during childhood and adolescence for Hodgkin’s disease. J Clin Oncol. 1987;5:239–245
  37. Green DM, Hyland A, Barcos MP, et al. Second malignant neoplasms after treatment for Hodgkin’s disease in childhood or adolescence. J Clin Oncol. 2000;18:1492–1499
  38. Metayer C, Lynch CF, Clarke EA, et al. Second cancers among long-term survivors of Hodgkin’s disease diagnosed in childhood and adolescence. J Clin Oncol. 2000;18:2435–2443
  39. Devita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970;73:881–895
  40. Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36:252–259
  41. Weiner MA, Leventhal B, Brecher ML, et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin’s disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol. 1997;15:2769–2779
  42. Donaldson SS. Hodgkin’s disease: Treatment with low dose radiation and chemotherapy. Front Radiat Ther Oncol. 1981;16:122–133
  43. Hunger SP, Link MP, Donaldson SS. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin’s disease: The Stanford experience. J Clin Oncol. 1994;12:2160–2166
  44. Weiner MA, Leventhal BG, Marcus R, et al. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin’s disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol. 1991;9:1591–1598
  45. Hudson MM, Greenwald C, Thompson E, et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin’s disease. J Clin Oncol. 1993;11:100–108
  46. Oberlin O, Leverger G, Pacquement H, et al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin’s disease: The experience of the French Society of Pediatric Oncology. J Clin Oncol. 1992;10:1602–1608
  47. Schellong G, Potter R, Bramswig J, et al. The German-Austrian Pediatric Hodgkin’s Disease Study Group High cure rates and reduced long-term toxicity in pediatric Hodgkin’s disease: The German-Austrian multicenter trial DAL-HD-90. J Clin Oncol. 1999;17:3736–3744
  48. Ruhl U, Albrecht M, Dieckmann K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin’s disease: An interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys. 2001;51:1209–1218
  49. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20:3765–3771
  50. Donaldson SS, Hudson MM, Lamborn KR, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin’s disease: Results of a prospective clinical trial. J Clin Oncol. 2002;20:3081–3087
  51. Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin’s disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol. 2000;18:1500–1507
  52. Ruhl U, Albrecht MR, Lueders H, et al. The German multinational GPOH-HD 95 trial: Treatment results and analysis of failures in pediatric Hodgkins disease using combination chemotherapy with and without radiation. Int J Radiat Oncol Biol Phys. 2004;60:S131;abstract
  53. Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med. 2003;348:2396–2406
  54. Sandoval C, Venkateswaran L, Billups C, et al. Lymphocyte-predominant Hodgkin disease in children. J Pediatr Hematol Oncol. 2002;24:269–273
  55. Karayalcin G, Behm FG, Gieser PW, et al. Lymphocyte predominant Hodgkin disease: Clinico-pathologic features and results of treatment—The Pediatric Oncology Group experience. Med Pediatr Oncol. 1997;29:519–525
  56. Nogova L, Reineke T, Josting A, et al. Lymphocyte-predominant Hodgkin s disease in clinical stage IA: Interim analysis of treatment options in three study generations of the German Hodgkin Study Group (GHSG). Blood. 2003;102:abstract 82
  57. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease. J Clin Oncol. 1999;17:776–783
  58. Schwartz CL. Special issues in pediatric Hodgkin’s disease. Eur J Haematol. 2005;66(suppl):55–62
  59. Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al. Lymphocyte-predominant Hodgkin’s lymphoma in children: Therapeutic abstention after initial lymph node resection—A study of the French Society of Pediatric Oncology. J Clin Oncol. 2003;21:2948–2952
  60. Murphy SB, Morgan ER, Katzenstein HM, et al. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol. 2003;25:684–687
  61. Rosenberg SA, Kaplan HS. Evidence for an orderly progression in the spread of Hodgkin’s disease. Cancer Res. 1966;26:1225–1231
  62. Kaplan HS. The radical radiotherapy of regionally localized Hodgkin’s disease. Radiology. 1962;78:533–561
  63. Prosnitz LR, Brizel DM, Light KL. Radiation techniques for the treatment of Hodgkin’s disease with combined modality therapy or radiation alone. Int J Radiat Oncol Biol Phys. 1997;39:885–895
  64. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst. 2005;97:1428–1437
  65. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21:3431–3439
  66. Hodgson DC, Zhang-Salomons J, Rothwell D, et al. Evolution of treatment for Hodgkin’s disease: A population-based study of radiation therapy use and outcome. Clin Oncol (R Coll Radiol). 2003;15:255–263
  67. Schonfeld SJ, Gilbert ES, Dores GM, et al. Acute myeloid leukemia following Hodgkin lymphoma: A population-based study of 35,511 patients. J Natl Cancer Inst. 2006;98:215–218
  68. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: The relation to age at treatment. J Clin Oncol. 2000;18:498–509
  69. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst. 2002;94:182–192
  70. Koh E, Tran T, Heydarian M, et al. A dosimetric study of mantle versus involved-field radiotherapy for Hodgkin’s lymphoma: Implications for second cancer risk and cardiac toxicity. In J Radiat Oncol Biol Phys. 2005;63:S422–S423
  71. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA. 1993;270:1949–1955
  72. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831–2837
  73. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol. 2004;22:3139–3148
  74. Pihkala J, Saarinen UM, Lundstrom U, et al. Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer. 1996;32A:97–103
  75. Polliack A. Late therapy-induced cardiac and pulmonary complications in cured patients with Hodgkin’s disease treated with conventional combination chemo-radiotherapy. Leuk Lymphoma. 1995;15:7–10
  76. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808–815
  77. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738–1743
  78. Kremer LC, van der Pal HJ, Offringa M, et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: A systematic review. Ann Oncol. 2002;13:819–829
  79. Kremer LC, van Dalen EC, Offringa M, et al. Frequency and risk factors of anthracycline-induced clinical heart failure in children: A systematic review. Ann Oncol. 2002;13:503–512
  80. Hudson MM, Krasin M, Link MP, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin’s disease. J Clin Oncol. 2004;22:4541–4550
  81. Marina NM, Greenwald CA, Fairclough DL, et al. Serial pulmonary function studies in children treated for newly diagnosed Hodgkin’s disease with mantle radiotherapy plus cycles of cyclophosphamide, vincristine, and procarbazine alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Cancer. 1995;75:1706–1711
  82. Fryer CJ, Hutchinson RJ, Krailo M, et al. Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin’s disease in children: A report from the Children’s Cancer Study Group. J Clin Oncol. 1990;8:1971–1980
  83. Catane R, Schwade JG, Turrisi AT, et al. Pulmonary toxicity after radiation and bleomycin: A review. Int J Radiat Oncol Biol Phys. 1979;5:1513–1518
  84. Villani F, Viviani S, Bonfante V, et al. Late pulmonary effects in favorable stage I and IIA Hodgkin’s disease treated with radiotherapy alone. Am J Clin Oncol. 2000;23:18–21
  85. Ortin TT, Shostak CA, Donaldson SS. Gonadal status and reproductive function following treatment for Hodgkin’s disease in childhood: The Stanford experience. Int J Radiat Oncol Biol Phys. 1990;19:873–880
  86. van den Berg H, Furstner F, van den Bos C, et al. Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin disease. Pediatr Blood Cancer. 2004;42:210–215
  87. Bramswig JH, Heimes U, Heiermann E, et al. The effects of different cumulative doses of chemotherapy on testicular function (Results in 75 patients treated for Hodgkin’s disease during childhood or adolescence). Cancer. 1990;65:1298–1302
  88. Constine LS, Donaldson SS, McDougall IR, et al. Thyroid dysfunction after radiotherapy in children with Hodgkin’s disease. Cancer. 1984;53:878–883
  89. Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin’s disease: Data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000;85:3227–3232
  90. Hutchinson RJ, Fryer CJ, Davis PC, et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin’s disease in children: Results of the Children’s Cancer Group Phase III Trial. J Clin Oncol. 1998;16:897–906
  91. Sackmann-Muriel F, Bonesana AC, Pavlovsky S, et al. Hodgkin’s disease in childhood: Therapy results in Argentina. Am J Pediatr Hematol Oncol. 1981;3:247–254
  92. Kung FH, Schwartz CL, Ferree CR, et al. POG 8625: A randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA1 Hodgkin disease: A report from the Children’s Oncology Group. J Pediatr Hematol Oncol. 2006;28:362–368
  93. Dorffel W, Luders H, Ruhl U, et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin’s disease in children and adolescents: Analysis and outlook. Klin Padiatr. 2003;215:139–145
  94. Kelly KM, Hutchinson RJ, Sposto R, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin’s lymphoma: Preliminary results from the Children’s Cancer Group Study CCG-59704. Ann Oncol. 2002;13(suppl 1):107–111
  95. Schwartz CL, Constine LS, London W, et al. POG 9425: Response-based, intensively timed therapy for intermediate/high stage (IS/HS) pediatric Hodgkin’s disease. Proc Am Soc Clin Oncol. 2002;21:abstract 1555
  96. Tebbi CK, Mendenhall N, London WB, et al. Treatment of stage I, IIA, IIIA(1) pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: A Pediatric Oncology Group (POG) study. Pediatr Blood Cancer. 2006;46:198–202
  97. Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines. Radiother Oncol. 2006;79:270–277
  98. Shahidi M, Kamangari N, Ashley S, et al. Site of relapse after chemotherapy alone for stage I and II Hodgkin’s disease. Radiother Oncol. 2006;78:1–5
  99. Constine LS, Marcus R, Chauvenet A, et al. Patterns of failure after response-based, dose-dense therapy for intermediate/high risk pediatric Hodgkin’s disease (POG 9425). In J Radiat Oncol Biol Phys. 2005;63:S21–S22
  100. Friedmann AM, Hudson MM, Weinstein HJ, et al. Treatment of unfavorable childhood Hodgkin’s disease with VEPA and low-dose, involved-field radiation. J Clin Oncol. 2002;20:3088–3094

PII: S1053-4296(07)00020-3

doi: 10.1016/j.semradonc.2007.02.009

Seminars in Radiation Oncology
Volume 17, Issue 3 , Pages 230-242 , July 2007

Article Tools

* Image Usage & Resolution